FDA launches digital health pilot, Dexcom first to gain entry qualification

FDA Launches Digital Health Pilot, Dexcom First to Qualify

On July 23, 2026, the U.S. Food and Drug Administration (FDA) officially announced the selection of Dexcom as the first participant in its "Technology Empowering Meaningful Patient Outcomes" (TEMPO) digital health device pilot. This milestone marks a critical step for the FDA in accelerating the integration of digital health technologies into mainstream healthcare.

Industry Background

In recent years, the potential of digital health and wearable devices in chronic disease management has become increasingly evident. However, the traditional premarket review process for medical devices is often lengthy and costly, limiting the rapid deployment of innovative technologies. At the same time, the Centers for Medicare & Medicaid Services (CMS) has been exploring payment reforms to support the adoption of digital health technologies. Against this backdrop, the FDA and CMS jointly launched the TEMPO pilot, aiming to accelerate the clinical validation and commercialization of digital health devices by integrating real-world data collection with payment mechanisms.

Key Developments

According to the FDA's announcement, the TEMPO pilot allows selected digital health devices to be exempt from certain premarket authorization requirements, instead collecting real-world data through a complementary CMS program. As the first participant, Dexcom plans to implement an AI-driven glucose health program. This program will integrate data from its prescription-grade G7 continuous glucose monitor (CGM) and the over-the-counter Stelo device, combined with contextual health information such as nutrition, physical activity, sleep, and stress, to provide users and healthcare providers with a comprehensive view of metabolic health.

Dexcom stated that participating in the pilot will help it generate real-world evidence on how glucose sensors and digital health programs can support earlier intervention strategies. This initiative is particularly aimed at screening and managing prediabetes and type 2 diabetes.

The complementary CMS program covers four key areas—hypertension, diabetes, heart disease, chronic kidney disease, musculoskeletal pain, anxiety, and depression—spanning 10 years, starting in July 2026. The FDA plans to accept up to 10 manufacturers per area and is still receiving letters of intent with no set deadline.

Market Impact

Dexcom's selection has a demonstrative effect on the entire digital health industry. Participating in the pilot means companies can gain market access in a shorter timeframe while reducing patient burden through CMS payment coverage, thereby accelerating product adoption. Other CGM manufacturers, such as Abbott and Medtronic, as well as digital health platform companies like Livongo (now part of Teladoc Health), may follow suit. Additionally, this pilot opens new pathways for AI-driven healthcare in chronic disease management, particularly in AI-based predictive analytics and personalized interventions.Hospitals and clinics are likely to adopt these real-world validated digital health devices more actively, especially those participating in CMS payment programs. For example, primary care facilities and endocrinology departments are expected to integrate Dexcom's AI-powered glucose monitoring into the screening and management workflows for prediabetic patients.

Challenges and Risks

Although the TEMPO pilot lowers the regulatory threshold, the quality and standardization of real-world data collection remain key challenges. Issues such as accuracy, privacy protection, and interoperability of digital health devices require ongoing attention. Furthermore, the FDA has not completely relaxed device performance requirements—exemptions are limited to certain premarket requirements, and manufacturers still need to demonstrate safety and effectiveness. For Dexcom, maintaining the robustness of its AI algorithm across different populations and avoiding health inequities will be critical tests in actual deployment.

Another risk is the limited coverage of CMS payments: currently focused on only four key areas and valid for 10 years, policy uncertainty may dampen long-term investment enthusiasm from companies.

Future Outlook

In the next 3 to 5 years, the TEMPO pilot is likely to become a new paradigm for the FDA in managing digital health devices. With more manufacturers participating and accumulating real-world evidence, regulators may further expand exemptions or even pursue permanent policy adjustments. CMS payment data will also provide insights into how the healthcare system can effectively cover digital health technologies.

On the technical front, the deep integration of AI and wearable devices will become a trend. By integrating multiple sensors and contextual data, Dexcom demonstrates the potential for digital health to evolve from "monitoring" to "intervention." Other areas, such as cardiac monitoring and respiratory disease management, may also replicate this model.

Returning to Industry Trends

From a broader perspective, the FDA's move reflects a shift in global regulators' attitudes toward digital health: from cautious observation to proactive guidance. Using policy innovation to promote industrial innovation while ensuring patient safety is becoming the mainstream approach. For medical technology companies, seizing pilot opportunities and accumulating high-quality real-world evidence will be key to winning market trust and payer recognition. On the capital side, more venture capital is expected to flow into companies with digital health device and AI capabilities, especially those with business models that can align with payers like CMS.

The concurrent loosening of regulations and payment reform is injecting strong momentum into the digital transformation of the healthcare industry.